Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2020 / Article

Research Article | Open Access

Volume 2020 |Article ID 7049812 | https://doi.org/10.1155/2020/7049812

Yongming Shuai, Zhili Jiang, Qiuwen Yuan, Shuqiang Tu, Fanhui Zeng, "Deciphering the Underlying Mechanism of Eucommiae Cortex against Osteoporotic Fracture by Network Pharmacology", Evidence-Based Complementary and Alternative Medicine, vol. 2020, Article ID 7049812, 12 pages, 2020. https://doi.org/10.1155/2020/7049812

Deciphering the Underlying Mechanism of Eucommiae Cortex against Osteoporotic Fracture by Network Pharmacology

Academic Editor: Antonella Fioravanti
Received01 May 2020
Accepted28 Aug 2020
Published07 Sep 2020


Background. Du Zhong (DZ), or Eucommiae Cortex, a traditional Chinese herbal medicine, has been used to treat osteoporosis. Although it has been reported that DZ can improve bone mass in ovariectomized rats, its pharmacological mechanisms in treating osteoporotic fractures (OPF) remain unclear. Methods. In this study, we used a network pharmacological manner to explore its potential complicated mechanism in treating OPF. We obtained DZ compounds from TCMSP and BATMAN-TCM databases and collected potential targets of these compounds through target fishing based on TCMSP and BATMAN-TCM databases. Next, we collected the OPF targets by using CTD, GeneCards, OMIM, HPO, and GenCLiP 3 databases. And then the overlapping genes between DZ potential targets and OPF targets were used to build up the protein-protein interaction (PPI) network and to analyze their interactions and find out the big hub genes in this network. Subsequently, clusterProfiler package in R language was utilized to conduct the enrichment of Gene Ontology biological process and KEGG pathways. Results. There were totally 93 active compounds and 916 related targets in DZ. After the enrichment analysis, we collected top 25 cellular biological processes and top 25 pathways based on the adjusted value and found that the DZ anti-OPF effect was mainly associated with the regulation of ROS and inflammatory response. Furthermore, 64 hub genes in PPI network, such as MAPK1 (degree = 41), SRC (degree = 39), PIK3R1 (degree = 36), VEGFA (degree = 31), TP53 (degree = 29), EGFR (degree = 29), JUN (degree = 29), AGT (degree = 29), MAPK1, SRC, PIK3R1, VEGFA, and TP53, were considered as potential therapeutic targets, implying the underlying mechanisms of DZ acting on OPF. Conclusion. We investigated the possible therapeutic mechanisms of DZ from a systemic perspective. These key targets and pathways provided promising directions for the future research to reveal the exact regulating mechanisms of DZ in treating OPF.

1. Introduction

Osteoporosis is a systemic bone disorder characterized by low bone density, poor bone quality, reduced bone strength, and an accompanying increased incidence of fractures [1]. The latest study noted that over 10 million people suffer from osteoporosis in the United States. Meanwhile, the treatment burden of osteoporosis, $22 billion in 2008, is expected to rise due to the consistently increasing aging population. Related osteoporosis treatments should be used to alleviate or reduce symptoms such as fractures, which could result in considerable cost savings [2]. Osteoporotic fractures (OPF) have serious consequences, such as declining functions and independence as well as increased morbidity and mortality [3, 4]. Hip fractures are considered to be the most expensive and debilitating of fractures because approximately 10 to 20% of patients will end up with a disability in the year following a hip fracture and half of patients will lose their independence. Osteoporotic fractures are also associated with motor function decline when occurring at other skeletal sites [5]. To curb bone loss, maintain bone mass, and decrease the risk of OPF, antiresorptive agents, anabolic agents, and bone mineral drugs have been widely used in clinical treatment [6]. However, it is noteworthy that almost all these antiosteoporosis treatments have limitations and side effects, such as increasing the risk of breast cancer, jaw necrosis, or atypical femur fracture [7, 8]. Therefore, alternative and safe intervention strategies may be promising.

Recently, traditional Chinese medicine (TCM) has attracted worldwide attention and has served as a main alternative treatment in East Asia, North America, and Europe due to its satisfactory curative effect, relatively low toxicity, and low cost [911]. TCM has been used in China for thousands of years, and it exerts a beneficial therapeutic effect and reduces side effects through multiple herb combinations to prevent and treat various diseases [12]. Meanwhile, TCM has increasingly been found to be effective in the treatment of osteoporosis [13, 14].

Du Zhong (DZ), or Eucommiae Cortex, is one of the most commonly used TCM herbs in the treatment of osteoporosis. DZ has been found to facilitate osteogenesis through activating osteoblasts and to inhibit osteolysis by suppressing osteoclast activity [15]. An animal experiment confirmed that Du Zhong Wan, consisting of Eucommiae Cortex and Radix Dipsaci, is capable of improving trabecular bone mineral density and bone biomechanical properties and thus plays a key role in the treatment of osteoporosis [16]. Although DZ exerted therapeutic effects against osteoporosis, the therapeutic mechanism of its exact is still unclear. Similar to TCM, DZ exerts its therapeutic efficacy by regulating multiple molecules in the human body. Therefore, it is still a major challenge to prove the mechanism of DZ through scientific trials that are used in Western medicine. Fortunately, the development of systems pharmacology offers researchers an alternative opportunity and an option to investigate the pharmacological mechanisms of TCM [17]. Recently, Wang et al. utilized a network pharmacology method to clarify the synergistic mechanism of Er-Xian decoction in treating osteoporosis [18]. Similarly, Gan et al. employed this systems pharmacology method to dissect the mechanisms of the therapeutic effect of Rhizoma Drynariae on osteoporosis [19].

In this network pharmacology work, we aim to comprehensively dissect the mechanisms of DZ in treating OPF. We collected related compounds of DZ from multiple databases and obtained the compounds’ potential targets via target fishing. Then, we matched these targets with OPF-related targets that were collected from a multisource database. Next, using overlapping targets obtained from the previous process, we built a protein-protein network to analyze their internal interactions and then screened out the hub genes. Furthermore, we used the clusterProfiler package in R to conduct biological process and KEGG pathway enrichment analyses. The protocol of our experimental procedures is shown in Figure 1.

2. Materials and Methods

2.1. Identification of Chemical Ingredients

To collect the active compounds of DZ, we utilized the Traditional Chinese Medicine System Pharmacology Database (TCMSP™, http://lsp.nwu.edu.cn/tcmsp.php) [20], which is a frequently used platform for systems pharmacology. The BATMAN-TCM platform (http://bionet.ncpsb.org/batman-tcm/) [21], one of the largest comprehensive TCM platforms, uses the similarity of known TCM drug–target interactions to predict potential compound–target interactions. In total, ninety-three chemical compounds were collected in this part.

2.2. Compound Screening and Target Prediction
2.2.1. OB Evaluation

Oral bioavailability (OB) refers to the percentage of an orally administered drug that reaches systemic circulation, and it is one of the most important pharmacokinetic profiles for drug screening. The TCMSP platform has adopted the OBioavail1.1 system, which integrates P450, 3A4, and P-glycoprotein information to obtain the OB value [22]. To determine the active ingredients used for further steps, we set the OB threshold at 30%.

2.2.2. DL Prediction

Drug-likeness (DL) is a qualitative index that represents the degree to which the target compound is “drug-like” and is used to remove chemically unsuitable compounds. TCMSP uses the Tanimoto similarity method to calculate the DL index by comparing the target compound to all 6511 molecules in the DrugBank database [23]. In this process, the compounds that did not meet the condition that DL ≥ 0.18 were removed.


To collect candidate compounds, we set the potential TAR score cutoff ≥20 and -value cutoff <0.05.

2.2.4. Target Prediction of the Active Ingredients

The compounds have effects on the targets that induce them to exert their biological functions. Thus, we used the TCMSP and BATMAN-TCM platforms to predict the targets of active compounds.

2.3. Disease Target Identification by Multiple Databases

We used multiple databases to collect OPF-related targets, and the terms “Osteoporotic” and “Fracture” were used as the key words for the search. The databases in this step included the Comparative Toxicogenomics Database (CTD, http://ctdbase.org/) [24], GeneCards (https://www.genecards.org/) [25], OMIM (https://www.omim.org/) [26], HPO (https://hpo.jax.org/app/) [27], and GenCLiP3 (http://ci.smu.edu.cn/genclip3/analysis.php) [28]. In total, three thousand four hundred-thirteen OPF targets were found through these databases. Then, we constructed a Venn diagram to determine the overlap between OPF and the active compound targets because these overlapping targets may play a critical role in the treatment of OPF. These targets were analyzed by String (https://string-db.org/) [29], in which the minimum required interaction score was set at the highest confidence level (0.900), and then, the protein-protein interaction (PPI) data were exported.

2.4. Network Construction
2.4.1. Construction Method

Two main networks were built in this process, including the compound-hub gene network and the hub gene-pathway network. The target information was obtained from the KEGG pathway enrichment results. Cytoscape 3.6.2 (http://www.cytoscape.org/) was used for all the network visualization work. Cytoscape 3.6.2 is one of most powerful open-source software programs for constructing different networks visually [30]. However, there are several limitations faced by network pharmacology research. For example, questions including whether compounds activate or inhibit targets, how they exact their effects on targets, whether they use binding or catalysis, and so on remain unclear.

2.4.2. Topological Feature Definition

We used three parameters to describe and quantify the importance of nodes in these networks because nodes that bridge many edges with their neighbors are more likely to exert crucial mediating functions. (1) “Degree” means the number of edges shared with other nodes. Examining the node’s degree is the most straightforward method of quantifying its centrality [31]. (2) “Betweenness centrality” is used to measure node centrality based on the shortest paths. A high-value node would play a more important role in the network because more regulation information will pass through it [32]. (3) “Closeness centrality” represents the mean distance between the node and all the other nodes in the network and is the reciprocal of the sum of the length of the shortest paths between a node and all the other nodes in the network. Therefore, the central node would be more likely to be close with all other nodes [33].

2.5. Biological Process and Pathway Enrichment Analysis

We used the clusterProfiler package in R (R 3.6.2 for Windows) to perform Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis to identify biological processes and systemic involvement of pathways.

3. Results

3.1. Active Compounds of DZ

A total of 147 related compounds were found in DZ collected from the TCMSP database, and of these, 27 candidate compounds remained after the screening of ADME thresholds (OB ≥ 30%, DL ≥ 0.18). Using the BATMAN-TCM database, we obtained 73 active compounds that matched the filter criteria. In total, we collected 93 unique compounds.

3.2. Target Prediction and Analysis

For these unique compounds, we obtained 961 unique related targets, 104 from TCMSP and 857 from BATMAN-TCM. We integrated the OPF genes that were obtained from multisource databases, including the CTD, GeneCards, OMIM, HPO, GenCLiP 3 databases, and a total of 3,834 related genes were collected. After construction of the Venn diagram, three hundred twenty-five overlapping targets between the related targets of DZ and OPF were selected as the key targets on which DZ exerts its anti-OPF effects (Figure 2).

The data obtained from the String database were used to establish the PPI network for the 325 overlapping targets. In this network, there were 249 nodes and 1006 edges in total. Then, three main parameters, namely, “degree”, “betweenness”, and “closeness”, were used as filters to select key genes and to build the large hub nodes to determine the anti-OPF effect of DZ. The first screening threshold was degree ≥ 6, closeness ≥ 0.312, and betweenness ≥ 0.000, which resulted in 122 nodes and 745 edges. Then, these 72 key nodes were further screened with a second threshold consisting of degree ≥ 11, closeness ≥ 0.340, and betweenness ≥ 0.016, and 64 nodes and 414 edges remained after this screening (Figure 3). These nodes included MAPK1, SRC, PIK3R1, VEGFA, TP53, EGFR, JUN, AGT, IL6, EGF, MAPK8, FOS, F2, FN1, EDN1, TNF, PPBP, ESR1, NCOA1, CTNNB1, NR3C1, ALB, RXRA, CBL, INS, PRKACA, AHSG, TGFB1, HSPA8, AR, FGF23, GNAS, NFKB1, GAS6, PRKCD, AVPR2, APOA1, PDGFB, HSP90AB1, IL4, HSPA1A, IGF2, SIRT1, PPARG, PPARA, CDC42, PGR, IFNG, CST3, NCOA3, TAC1, PLCB1, NOS3, CCL5, FGF2, ESR2, STAT5A, WNT5A, HTR2C, HTR2A, CCL2, CRH, APOE, and CFD (Table 1). After sorting these 64 big hub nodes in descending order, we found that MAPK1 (degree = 41), SRC (degree = 39), PIK3R1 (degree = 36), VEGFA (degree = 31), TP53 (degree = 29), EGFR (degree = 29), JUN (degree = 29), AGT (degree = 29), IL6 (degree = 28), EGF (degree = 27), MAPK8 (degree = 26), FOS (degree = 25), and F2 (degree = 25) were the most important targets in this PPI network.

UniProt IDGene symbolDescriptionDegree

Q499G7MAPK1Mitogen-activated protein kinase 141
P12931SRCSRC proto-oncogene, non–receptor tyrosine kinase39
P27986PIK3R1Phosphoinositide-3-kinase regulatory subunit 136
P15692VEGFAVascular endothelial growth factor A31
Q53GA5TP53Tumor protein p5329
Q504U8EGFREpidermal growth factor receptor29
P05412JUNJun proto-oncogene29
Q75MH2IL6Interleukin 628
P01133EGFEpidermal growth factor27
P45983MAPK8Mitogen-activated protein kinase 826
Q6FG41FOSFos proto-oncogene25
P00734F2Coagulation factor II, thrombin25
Q9UQS6FN1Fibronectin 124
Q6FH53EDN1Endothelin 124
Q5STB3TNFTumor necrosis factor24
P02775PPBPPro-platelet basic protein24
Q9UBT1ESR1Estrogen receptor 123
Q15788NCOA1Nuclear receptor coactivator 123
P35222CTNNB1Catenin beta 123
P04150NR3C1Nuclear receptor subfamily 3 group C member 123
Q6P3U7RXRARetinoid X receptor alpha21
P22681CBLCbl proto-oncogene21
P17612PRKACAProtein kinase cAMP-activated catalytic subunit alpha18
P02765AHSGAlpha 2-HS glycoprotein18
P01137TGFB1Transforming growth factor beta 118
V9HW22HSPA8Heat shock protein family A (Hsp70) member 817
Q9NUA2ARAndrogen receptor17
Q9GZV9FGF23Fibroblast growth factor 2317
Q5JWF2GNASGNAS complex locus16
P19838NFKB1Nuclear factor kappa B subunit 116
Q14393GAS6Growth arrest specific 615
Q05655PRKCDProtein kinase C delta15
P30518AVPR2Arginine vasopressin receptor 215
P02647APOA1Apolipoprotein A115
P01127PDGFBPlatelet-derived growth factor subunit B15
Q6PK50HSP90AB1Heat shock protein 90 alpha family class B member 114
Q5FC01IL4Interleukin 414
P0DMV9HSPA1AHeat shock protein family A (Hsp70) member 1A14
P01344IGF2Insulin-like growth factor 214
Q96EB6SIRT1Sirtuin 113
Q4W448PPARGPeroxisome proliferator activated receptor gamma13
Q07869PPARAPeroxisome proliferator activated receptor alpha13
P60953CDC42Cell division cycle 4213
P06401PGRProgesterone receptor13
P01579IFNGInterferon gamma13
P01034CST3Cystatin C13
Q9Y6Q9NCOA3Nuclear receptor coactivator 312
Q9Y494TAC1Tachykinin precursor 112
Q9NQ66PLCB1Phospholipase C beta 112
P29474NOS3Nitric oxide synthase 312
P13501CCL5C-C motif chemokine ligand 512
P09038FGF2Fibroblast growth factor 212
Q92731ESR2Estrogen receptor 211
Q59GY7STAT5ASignal transducer and activator of transcription 5A11
P41221WNT5AWnt family member 5A11
P28335HTR2C5-Hydroxytryptamine receptor 2C11
P28223HTR2A5-Hydroxytryptamine receptor 2A11
P13500CCL2C-C motif chemokine ligand 211
P06850CRHCorticotropin releasing hormone11
P02649APOEApolipoprotein E11
P00746CFDComplement factor D11

Then, we further built the big hub nodes-compound network (Figure 4) based on these 64 key targets. This network included 40 compound nodes and 64 large hub target nodes. Subsequently, we reordered these compound nodes in descending order of degree and found that Civetone was relevant to 25 large hub genes, Epiquinidine to 19 genes, quercetin to 13 genes, Gamma-Sitosterol to 7 genes, and Pinosylvin to 7 genes.

3.3. GO Biological Process Enrichment Analysis

After sorting the 343 biological process (BP) terms in ascending order of adjusted value, we found that the top 25 biological processes (Figure 5) mainly concentrated on aspects of the reactive oxygen species metabolic process and its response to nutrient levels and epithelial cell proliferation. The following processes showed an enriched gene ratio: gland development (GO:0048732, 18.6%), response to nutrient levels (GO:0031667, 18.6%), response to a molecule of bacterial origin (GO:0002237, 15.5%), response to lipopolysaccharide (GO:0032496, 15.2%), response to an antibiotic (GO:0046677, 14.6%), reactive oxygen species metabolic process (GO:0072593, 13.6%), response to oxidative stress (GO:0006979, 16.4%), steroid metabolic process (GO:0008202, 14.2%), cellular response to drug (GO:0035690, 14.9%), epithelial cell proliferation (GO:0050673, 15.8%), response to a steroid hormone (GO:0048545, 14.9%), response to reactive oxygen species (GO:0000302, 11.8%), second-messenger-mediated signaling (GO:0019932, 15.2%), reproductive structure development (GO:0048608, 14.9%), calcium ion transport (GO:0006816, 14.9%), reproductive system development (GO:0061458, 14.9%), regulation of peptide secretion (GO:0002791, 15.8%), response to xenobiotic stimulus (GO:0009410, 12.4%), regulation of membrane potential (GO:0042391, 14.6%), cellular response to oxidative stress (GO:0034599, 12.4%), regulation of epithelial cell proliferation (GO:0050678, 13.6%), divalent metal ion transport (GO:0070838, 15.2%), divalent inorganic cation transport (GO:0072511, 15.2%), negative regulation of response to external stimulus (GO:0032102, 13.3%), and branching morphogenesis of an epithelial tube (GO:0048754, 9.3%). Based on these BP enrichment analyses, we found that the anti-OPF effect of DZ may result from its regulatory effect on the reactive oxygen species metabolic process, response to nutrient levels, and epithelial cell proliferation.

3.4. KEGG Pathway Enrichment Analysis

We conducted further KEGG pathway enrichment analyses of the 325 overlapping genes to determine the potential therapeutic mechanism of DZ for OPF. Then, we sorted 25 pathways based on the adjusted value (Figure 6). These pathways were the AGE-RAGE signaling pathway in diabetic complications (hsa04933, 9.6%), the estrogen signaling pathway (hsa04915, 11.1%), proteoglycans in cancer (hsa05205, 11.8%), fluid shear stress and atherosclerosis (hsa05418, 8.6%), parathyroid hormone synthesis, secretion, and action (hsa04928, 7.5%), breast cancer (hsa05224, 8.6%), Cushing’s syndrome (hsa04934, 8.6%), prostate cancer (hsa05215, 6.8%), the cAMP signaling pathway (hsa04024, 10%), morphine addiction (hsa05032, 6.4%), African trypanosomiasis (hsa05143, 4.3%), the GnRH signaling pathway (hsa04912, 6.4%), endocrine resistance (hsa01522, 6.4%), gastric cancer (hsa05226, 7.9%), neuroactive ligand-receptor interaction (hsa04080, 12.1%), the MAPK signaling pathway (hsa04010, 11.1%), the calcium signaling pathway (hsa04020, 8.6%), the oxytocin signaling pathway (hsa04921, 7.5%), malaria (hsa05144, 4.3%), Th17 cell differentiation (hsa04659, 6.1%), the HIF-1 signaling pathway (hsa04066, 6.1%), colorectal cancer (hsa05210, 5.4%), GnRH secretion (hsa04929, 4.6%), cortisol synthesis and secretion (hsa04927, 4.6%), and the TNF signaling pathway (hsa04668, 6.1%) (Table 2). We also simultaneously constructed the target-pathway network based on the DZ targets enriched in each pathway (Figure 7).

IDDescription. adjustCount

hsa04933AGE-RAGE signaling pathway in diabetic complications4.29750564649423e-1527
hsa04915Estrogen signaling pathway4.29750564649423e-1531
hsa05205Proteoglycans in cancer7.02978144058047e-1233
hsa05418Fluid shear stress and atherosclerosis3.50540676797616e-0924
hsa04928Parathyroid hormone synthesis, secretion, and action3.50540676797616e-0921
hsa05224Breast cancer8.65129662473866e-0924
hsa04934Cushing syndrome2.25061036469472e-0824
hsa05215Prostate cancer2.25061036469472e-0819
hsa04024cAMP signaling pathway4.25537215261066e-0828
hsa05032Morphine addiction4.35290458036493e-0818
hsa05143African trypanosomiasis5.25038311520481e-0812
hsa04912GnRH signaling pathway5.25038311520481e-0818
hsa01522Endocrine resistance1.16942061208876e-0718
hsa05226Gastric cancer1.53049773606446e-0722
hsa04080Neuroactive ligand-receptor interaction3.92997114777747e-0734
hsa04010MAPK signaling pathway4.75554213381079e-0731
hsa04020Calcium signaling pathway8.10557748077706e-0724
hsa04921Oxytocin signaling pathway1.09530352609987e-0621
hsa04659Th17 cell differentiation1.90497387620456e-0617
hsa04066HIF-1 signaling pathway2.39525818923615e-0617
hsa05210Colorectal cancer2.67545458381123e-0615
hsa04929GnRH secretion2.67545458381123e-0613
hsa04927Cortisol synthesis and secretion3.01425725456316e-0613
hsa04668TNF signaling pathway3.01425725456316e-0617

4. Discussion

Osteoporosis is becoming a serious health burden due to the aging population. Therefore, prevention of osteoporosis and of osteoporotic fracture has considerable social and economic significance [34]. Drug therapy, such as bisphosphonates and denosumab, is a practical way to treat osteoporosis by inhibiting osteoclast development, formation, and survival [35, 36]. Although these antiresorptive drugs are effective in treating osteoporosis, the long-term use or high dosage of these drugs can cause serious side effects, such as atypical long bone fractures and jaw osteonecrosis [37, 38]. In terms of fracture healing, the use of bisphosphonates remains controversial because callus remodeling is impaired in testing on ovariectomized rats [39]. Furthermore, these antiresorptive drugs cannot rebuild bone that is lost in the progression of osteoporosis, so there is a need to find a method capable of promoting bone building [40].

DZ has been found to alleviate improved osteoblast activity and reverse bone loss in ovariectomized (OVX) mice, which may result from the interaction between its active compounds and related targets. Thus, we investigated the anti-OPF mechanism of DZ through a network pharmacology method. Based on the big hub genes-compounds network (Figure 4), we found that five key compounds, including Civetone, Epiquinidine, quercetin, Gamma-Sitosterol, and Pinosylvin, play dominant roles in this network. Therefore, these active compounds may lay the foundation for the promising anti-OPF effect of DZ.

In the present study, 325 common gene targets of DZ and OPF were identified and 64 hub genes were identified that may play critical roles in this treatment. Some anti-OPF effects of these genes have been confirmed by clinical trials or animal experiments. Chow et al. found that low-magnitude high-frequency vibration stimulation is able to promote fracture healing by positively regulating the impaired innate immune response (lower expression of TNF-α and IL-6) and promoting macrophage polarization in delayed osteoporotic fracture healing [41]. Wang et al. suggested that organic gallium can improve osteoporotic fracture healing by positively modulating the OPG/RANKL ratio and inhibiting the expression of TNF-α and IL-6 [42]. Zhang et al. found that 17β-estradiol, which is used in the clinic to prevent and treat postmenopausal women with osteoporotic fracture, can significantly downregulate ROS production and the expression of TNF-α and IL-1β, as well as the phosphorylation of ERK2 (MAPK1) [43]. Wang et al. suggested that ESR1 is a susceptibility gene for osteoporotic fracture in postmenopausal Chinese women [44]. De-Ugarte et al. found that miR-320a, which is known to target CTNNB1 of osteoblasts, is overexpressed in osteoporotic fractures [45]. Swanberg et al. found that elderly women who were carriers of the IFNG variant alleles had lower BMD and a lower risk of incident fracture [46]. Based on a large population-based cohort study, Rivadeneira et al. found that ESR2 variants were related to an increased risk of fragility fracture in postmenopausal women [47]. These gene targets play key roles in osteoblast differentiation and osteoclastogenesis during fracture repair. Moreover, the results presented in Figure 4 show that one active compound can interact with multiple genes, one gene with dicompound can interact with multiple genes, and one gene can interact with different compounds, which is in accordance with the modern drug theory of “multi-ingredient, multitarget” [48].

We conducted GO biological process and KEGG enrichment analyses of the overlapping genes to identify their functions. We found 44 (13.6%) genes involved in reactive oxygen species metabolic processes. Reactive oxygen species play key roles in regulating cell proliferation, apoptosis, migration, and differentiation [49], as well as in the regulation of osteoclasts and osteoblasts [50, 51]. EGFR is the overlapping gene between reactive oxygen species (ROS) and the PI3K-Akt signaling pathway (27 genes enriched, 9.6%) based on the results of the GOBP and KEGG pathway enrichment analyses. The PI3K-Akt signaling pathway was first found in tumor cells and proved to regulate numerous cell functions, and it has been proven to be related to the promotion of osteogenesis by upregulating the proliferation and differentiation of bone marrow mesenchymal stem cells [5254]. Furthermore, activation of the EGFR-Akt-mTOR pathway can effectively protect osteoblasts against dexamethasone, which increases the level of ROS production in osteoblastic cells [55]. MAPK1 is a common gene in reactive oxygen species, the PI3K-Akt signaling pathway, the MAPK signaling pathway (31 genes enriched, 11.1%), and the TNF signaling pathway. MAPKs play important roles in cell proliferation, differentiation, and apoptosis, as well as in regulating inflammation [56]. ROS can lead to serious periodontal tissue destruction by promoting osteoclastic bone resorption, which is closely related to the protein expression of MAPKs and NF-κB [57]. Srinivasa et al. found that the facilitation of ROS on osteoclast differentiation and resorption can be reversed by inhibiting the NF-κB and calcineurin-NFAT pathways [58]. The activation of MAPKs also plays a key role in osteoclastogenesis induced by RANKL. However, these ROS-directed upregulations of MAPK and NF-κB signaling can be attenuated by strengthening the nuclear factor-erythroid 2-related factor 2 [59]. Therefore, the anti-OPF effect of DZ may depend on the regulatory effect on ROS through these key genes and pathways.

Forty-five (13.9%) genes were involved in the regulation of the inflammatory response. In vitro and in vivo studies have shown that the proinflammatory cytokines IL-6 and TNF-α are involved in the pathogenesis of osteoporosis and influence bone metabolism [60, 61]. Several studies have also found that high expression of inflammatory markers is closely related to increased bone loss [6264] and that these markers are also risk factors for incidents of nontraumatic fractures. Women with increased expression of inflammatory markers have a 3-fold risk of hip fractures [65]. IL-6 and TNF-α are the overlapping genes between the regulation of inflammatory response (17 genes enriched, 6.1%) and the TNF signaling pathway (45 genes enriched, 13.9%) based on the results of the BP and KEGG pathway enrichment analyses. Ali Aydin et al. found higher expression levels of TNF- α and IL-6 in OVX model rats, and these cytokines reached their apex when a fracture occurred [66]. Moreover, these cytokines also increase the production of oxygen radicals, which can enhance osteoclastic activity while decreasing osteoblastic activity [67, 68]. Therefore, the anti-OPF effect of DZ may depend on the regulation of the inflammatory response through these key genes and pathways.

5. Conclusion

By utilizing network pharmacology, we investigated the potential targets of DZ and the underlying mechanism of its anti-OPF effects, which may be based on the regulation of ROS and the inflammatory response. According to the KEGG pathway enrichment results, we found that the PI3K-Akt signaling pathway, MAPK signaling pathway, and TNF signaling pathway may be the main pathways in treating OPF. Thus, we believe that the anti-OPF effect of DZ is mainly based on its direct or indirect regulation of the abovementioned potential targets and pathways and that DZ provides promising directions for future research, which is essential to reveal its exact regulatory mechanisms.


DZ:Du Zhong
OPF:Osteoporotic fractures
TCM:Traditional Chinese medicine
TCMSP:Traditional Chinese Medicine System Pharmacology Database
OB:Oral bioavailability
CTD:Comparative Toxicogenomics Database
OMIM:Online Mendelian Inheritance in Man
HPO:Human Phenotype Ontology
PPI:Protein-protein interaction
KEGG:Kyoto Encyclopedia of Genes and Genomes
GO:Gene Ontology
BP:Biological process
ROS:Reactive oxygen species.

Data Availability

All our main data used to support the findings of this study have been deposited in the Figshare repository (https://doi.org/10.6084/m9.figshare.12152607.v1).

Conflicts of Interest

The authors declare that they have no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Yongming Shuai and Fanhui Zeng conceived the idea of this article and supervised the research. Yongming Shuai performed the research, analyzed the data, and wrote the manuscript. Zhili Jiang and Qiuwen Yuan performed Target prediction and analysis as well as related enrichment processes. Shuqiang Tu and Fanhui Zeng participated in revising the data and improving manuscript writing. All authors reviewed the manuscript. And all authors read and approved the final version of the manuscript.


  1. P. M. Camacho, S. M. Petak, N. Binkley et al., “American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis–2016,” Endocrine Practice, vol. 22, no. 4, pp. 1–42, 2016. View at: Publisher Site | Google Scholar
  2. E. M. Lewiecki, J. D. Ortendahl, J. Vanderpuye-Orgle et al., “Healthcare policy changes in osteoporosis can improve outcomes and reduce costs in the United States.,” JBMR Plus, vol. 3, Article ID e10192, 2019. View at: Publisher Site | Google Scholar
  3. J. A. Cauley, “Public health impact of osteoporosis,” Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences, vol. 68, no. 10, pp. 1243–1251, 2013. View at: Publisher Site | Google Scholar
  4. M. A. Clynes, N. C. Harvey, E. M. Curtis, N. R. Fuggle, E. M. Dennison, and C. Cooper, “The epidemiology of osteoporosis.,” British Medical Bulletin, vol. 133, pp. 105–117, 2020. View at: Google Scholar
  5. E. M. Lewiecki, B. Chastek, K. Sundquist et al., “Osteoporotic fracture trends in a population of US managed care enrollees from 2007 to 2017,” Osteoporosis International, vol. 31, no. 7, pp. 1299–1304, 2020. View at: Publisher Site | Google Scholar
  6. J.-G. Letarouilly, O. Broux, and A. Clabaut, “New insights into the epigenetics of osteoporosis,” Genomics, vol. 111, no. 4, pp. 793–798, 2019. View at: Publisher Site | Google Scholar
  7. M. Kharazmi, J. Schilcher, P. Hallberg, and K. Michaëlsson, “Bisphosphonate-associated atypical fractures of the femur: an update of the current evidence,” Lakartidningen, vol. 116, 2019. View at: Google Scholar
  8. O. Tabatabaei-Malazy, P. Salari, P. Khashayar, and B. Larijani, “New horizons in treatment of osteoporosis,” Daru Journal of Pharmaceutical Sciences, vol. 25, no. 1, 2017. View at: Publisher Site | Google Scholar
  9. L.-J. Xiao and R. Tao, “Traditional Chinese medicine (TCM) therapy,” Advances in Experimental Medicine and Biology, vol. 1010, pp. 261–280, 2017. View at: Publisher Site | Google Scholar
  10. W. Xu, A. D. Towers, P. Li, and J.-P. Collet, “Traditional Chinese medicine in cancer care: Perspectives and experiences of patients and professionals in China,” European Journal of Cancer Care, vol. 15, no. 4, pp. 397–403, 2006. View at: Publisher Site | Google Scholar
  11. T.-T. Sham, C.-O. Chan, Y.-H. Wang, J.-M. Yang, D. Kam-Wah Mok, and S.-W. Chan, “A review on the traditional Chinese medicinal herbs and formulae with hypolipidemic effect,” BioMed Research International, vol. 2014, Article ID 925302, pp. 1–21, 2014. View at: Publisher Site | Google Scholar
  12. P. Li, L.-p. Yang, and Y.-w. Gong, “Application of systems biology technology in research of traditional Chinese medicine,” Journal of Traditional Chinese Medicine, vol. 29, no. 2, pp. 153–157, 2009. View at: Publisher Site | Google Scholar
  13. L. P. Zhou, K. Y. Wong, H. T. Yeung et al., “Bone protective effects of danggui buxue tang alone and in combination with tamoxifen or raloxifene in vivo and in vitro.,” Frontiers in Pharmacology, vol. 9, p. 779, 2018. View at: Publisher Site | Google Scholar
  14. F. Gu, J. Jiang, S. Wang et al., “An experimental research into the potential therapeutic effects of anti-osteoporosis decoction and Yougui pill on ovariectomy-induced osteoporosis,” American Journal of Translational Research, vol. 11, no. 9, pp. 6032–6039, 2019. View at: Google Scholar
  15. H. Ha, J. Ho, S. Shin et al., “Effects of Eucommiae Cortex on osteoblast-like cell proliferation and osteoclast inhibition,” Archives of Pharmacal Research, vol. 26, no. 11, pp. 929–936, 2003. View at: Publisher Site | Google Scholar
  16. F. Li, X. Yang, J. Bi, Z. Yang, and C. Zhang, “Antiosteoporotic activity of Du-Zhong-Wan water extract in ovariectomized rats,” Pharmaceutical Biology, vol. 54, no. 9, pp. 1857–1864, 2016. View at: Publisher Site | Google Scholar
  17. W. Zhang, Y. Huai, Z. Miao, A. Qian, and Y. Wang, “Systems pharmacology for investigation of the mechanisms of action of traditional chinese medicine in drug discovery,” Frontiers in Pharmacology, vol. 10, p. 743, 2019. View at: Publisher Site | Google Scholar
  18. N. Wang, P. Xu, X. Wang et al., “Integrated pathological cell fishing and network pharmacology approach to investigate main active components of Er-Xian decotion for treating osteoporosis,” Journal of Ethnopharmacology, vol. 241, Article ID 111977, 2019. View at: Publisher Site | Google Scholar
  19. D. Gan, X. Xu, D. Chen, P. Feng, and Z. Xu, “Network pharmacology-based pharmacological mechanism of the Chinese medicine rhizoma drynariae against osteoporosis,” Medical Science Monitor, vol. 25, pp. 5700–5716, 2019. View at: Publisher Site | Google Scholar
  20. J. Ru, P. Li, J. Wang et al., “TCMSP: A database of systems pharmacology for drug discovery from herbal medicines.,” Journal of Cheminformatics, vol. 6, no. 1, p. 13, 2014. View at: Publisher Site | Google Scholar
  21. Z. Liu, F. Guo, Y. Wang et al., “BATMAN-TCM: A bioinformatics analysis tool for molecular mechANism of traditional Chinese medicine,” Scientific Reports, vol. 6, no. 1, Article ID 21146, 2016. View at: Publisher Site | Google Scholar
  22. X. Xu, W. Zhang, C. Huang et al., “A novel chemometric method for the prediction of human oral bioavailability,” International Journal of Molecular Sciences, vol. 13, no. 6, pp. 6964–6982, 2012. View at: Publisher Site | Google Scholar
  23. W. Tao, X. Xu, X. Wang et al., “Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease,” Journal of Ethnopharmacology, vol. 145, no. 1, pp. 1–10, 2013. View at: Publisher Site | Google Scholar
  24. C. J. Grondin, A. P. Davis, T. C. Wiegers, J. A. Wiegers, and C. J. Mattingly, “Accessing an expanded exposure science module at the comparative Toxicogenomics database.,” Environmental Health Perspectives, vol. 126, no. 1, Article ID 014501, 2018. View at: Publisher Site | Google Scholar
  25. M. Rebhan, V. Chalifa-Caspi, J. Prilusky, and D. Lancet, “GeneCards: A novel functional genomics compendium with automated data mining and query reformulation support,” Bioinformatics, vol. 14, no. 8, pp. 656–664, 1998. View at: Publisher Site | Google Scholar
  26. J. S. Amberger and A. Hamosh, “Searching online mendelian inheritance in man (OMIM): A knowledgebase of human genes and genetic phenotypes.,” Current Protocols in Bioinformatics, vol. 58, no. 1, 2017. View at: Publisher Site | Google Scholar
  27. P. N. Robinson, S. Köhler, S. Bauer, D. Seelow, D. Horn, and S. Mundlos, “The Human phenotype ontology: A tool for annotating and analyzing human hereditary disease,” The American Journal of Human Genetics, vol. 83, no. 5, pp. 610–615, 2008. View at: Publisher Site | Google Scholar
  28. J. H. Wang, L. F. Zhao, H. F. Wang et al., “GenCLiP 3: Mining human genes’ functions and regulatory networks from pubMed based on co-occurrences and natural language processing,” Bioinformatics, vol. 36, no. 6, pp. 1973–1975, 2019. View at: Google Scholar
  29. D. Szklarczyk, J. H. Morris, H. Cook et al., “The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible,” Nucleic Acids Research, vol. 45, no. D1, pp. D362–D368, 2017. View at: Publisher Site | Google Scholar
  30. P. Shannon, A. Markiel, and O. Ozier, “Cytoscape: A software environment for integrated models of biomolecular interaction networks,” Genome Research, vol. 13, no. 11, pp. 2498–2504, 2003. View at: Publisher Site | Google Scholar
  31. P. V. Missiuro, K. Liu, L. Zou et al., “Information flow analysis of interactome networks,” PLOS Computational Biology, vol. 5, no. 4, Article ID e1000350, 2009. View at: Publisher Site | Google Scholar
  32. K. Raman, N. Damaraju, and G. K. Joshi, “The organisational structure of protein networks: Revisiting the centrality-lethality hypothesis,” Systems and Synthetic Biology, vol. 8, no. 1, pp. 73–81, 2014. View at: Publisher Site | Google Scholar
  33. Y. Tang, M. Li, J. Wang, Y. Pan, and F.-X. Wu, “CytoNCA: A cytoscape plugin for centrality analysis and evaluation of protein interaction networks,” Biosystems, vol. 127, pp. 67–72, 2015. View at: Publisher Site | Google Scholar
  34. P. Mitchell, K. Åkesson, M. Chandran, C. Cooper, K. Ganda, and M. Schneider, “Implementation of models of care for secondary osteoporotic fracture prevention and orthogeriatric models of care for osteoporotic hip fracture,” Best Practice & Research Clinical Rheumatology, vol. 30, no. 3, pp. 536–558, 2016. View at: Publisher Site | Google Scholar
  35. R. G. G. Russell, N. B. Watts, F. H. Ebetino, and M. J. Rogers, “Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy,” Osteoporosis International, vol. 19, no. 6, pp. 733–759, 2008. View at: Publisher Site | Google Scholar
  36. S. Fukumoto and T. Matsumoto, “Recent advances in the management of osteoporosis,” F1000Research, vol. 6, p. 625, 2017. View at: Publisher Site | Google Scholar
  37. M. Rossini, G. Adami, S. Adami, O. Viapiana, and D. Gatti, “Safety issues and adverse reactions with osteoporosis management,” Expert Opinion on Drug Safety, vol. 15, no. 3, pp. 321–332, 2016. View at: Publisher Site | Google Scholar
  38. M. Kharazmi, P. Hallberg, G. Warfvinge, and K. Michaëlsson, “Risk of a typical femoral fractures and osteonecrosis of the jaw associated with alendronate use compared with other oral bisphosphonates,” Rheumatology, vol. 53, no. 10, pp. 1911–1913, 2014. View at: Publisher Site | Google Scholar
  39. T. Savaridas, R. J. Wallace, D. M. Salter, and A. H. R. W. Simpson, “Do bisphosphonates inhibit direct fracture healing?” The Bone & Joint Journal, vol. 95-B, no. 9, pp. 1263–1268, 2013. View at: Publisher Site | Google Scholar
  40. J. Wang, K. Su, W. Sang, L. Li, and S. Ma, “Thiazide diuretics and the incidence of osteoporotic fracture: A systematic review and meta-analysis of cohort studies.,” Frontiers in Pharmacology, vol. 10, p. 1364, 2019. View at: Publisher Site | Google Scholar
  41. S.-H. Chow, Y.-N. Chim, J. Wang et al., “Vibration treatment modulates macrophage polarisation and enhances early inflammatory response in oestrogen-deficient osteoporotic-fracture healing,” European Cells and Materials, vol. 38, pp. 228–245, 2019. View at: Publisher Site | Google Scholar
  42. J. Wang, M. He, G. Wang, and Q. Fu, “Organic gallium treatment improves osteoporotic fracture healing through affecting the OPG/RANKL ratio and expression of serum inflammatory cytokines in ovariectomized rats,” Biological Trace Element Research, vol. 183, no. 2, pp. 270–279, 2018. View at: Publisher Site | Google Scholar
  43. Y. Zhang, Y. He, Y. Zong et al., “17 -estradiol attenuates homocysteine-induced oxidative stress and inflammatory response as well as MAPKs cascade via activating PI3-K/Akt signal transduction pathway in Raw 264.7 cells,” Acta Biochimica et Biophysica Sinica, vol. 47, no. 2, pp. 65–72, 2015. View at: Publisher Site | Google Scholar
  44. C. Wang, Z. Zhang, H. Zhang et al., “Susceptibility genes for osteoporotic fracture in postmenopausal Chinese women,” Journal of Bone and Mineral Research, vol. 27, no. 12, pp. 2582–2591, 2012. View at: Publisher Site | Google Scholar
  45. L. De-Ugarte, G. Yoskovitz, S. Balcells et al., “MiRNA profiling of whole trabecular bone: Identification of osteoporosis-related changes in MiRNAs in human hip bones.,” BMC Medical Genomics, vol. 8, no. 1, p. 75, 2015. View at: Publisher Site | Google Scholar
  46. M. Swanberg, F. E. McGuigan, K. K. Ivaska, P. Gerdhem, and K. Åkesson, “Polymorphisms in the inflammatory genes CIITA, CLEC16A and IFNG influence BMD, bone loss and fracture in elderly women,” PLoS One, vol. 7, no. 10, Article ID e47964, 2012. View at: Publisher Site | Google Scholar
  47. F. Rivadeneira, J. B. J. van Meurs, J. Kant et al., “Estrogen receptor β (ESR2) polymorphisms in interaction with estrogen receptor α (ESR1) and insulin-like growth factor I (IGF1) variants influence the risk of fracture in postmenopausal women,” Journal of Bone and Mineral Research, vol. 21, no. 9, pp. 1443–1456, 2006. View at: Publisher Site | Google Scholar
  48. S. Sheng, J. Wang, L. Wang et al., “Network pharmacology analyses of the antithrombotic pharmacological mechanism of Fufang Xueshuantong capsule with experimental support using disseminated intravascular coagulation rats,” Journal of Ethnopharmacology, vol. 154, no. 3, pp. 735–744, 2014. View at: Publisher Site | Google Scholar
  49. V. Domazetovic, G. Marcucci, T. Iantomasi, M. L. Brandi, and M. T. Vincenzini, “Oxidative stress in bone remodeling: Role of antioxidants,” Clinical Cases in Mineral and Bone Metabolism, vol. 14, no. 2, pp. 209–216, 2017. View at: Publisher Site | Google Scholar
  50. K. Schröder, “NADPH oxidases in bone homeostasis and osteoporosis,” Free Radical Biology and Medicine, vol. 132, pp. 67–72, 2019. View at: Publisher Site | Google Scholar
  51. X. Gan, S. Huang, Q. Yu, H. Yu, and S. S. Yan, “Blockade of Drp1 rescues oxidative stress-induced osteoblast dysfunction,” Biochemical and Biophysical Research Communications, vol. 468, no. 4, pp. 719–725, 2015. View at: Publisher Site | Google Scholar
  52. G. Luo, B. Xu, and Y. Huang, “Icariside II promotes the osteogenic differentiation of canine bone marrow mesenchymal stem cells via the PI3K/AKT/mTOR/S6K1 signaling pathways,” American Journal of Translational Research, vol. 9, pp. 2077–2087, 2017. View at: Google Scholar
  53. G. Li, J. Hu, H. Chen et al., “Enamel matrix derivative enhances the proliferation and osteogenic differentiation of human periodontal ligament stem cells on the titanium implant surface,” Organogenesis, vol. 13, no. 3, pp. 103–113, 2017. View at: Publisher Site | Google Scholar
  54. Y. Tong, W. Feng, Y. Wu et al., “Mechano-growth factor accelerates the proliferation and osteogenic differentiation of rabbit mesenchymal stem cells through the PI3K/AKT pathway,” BMC Biochemistry, vol. 16, no. 1, p. 1, 2015. View at: Publisher Site | Google Scholar
  55. J.-b. Fan, W. Liu, X.-h. Zhu et al., “EGFR-AKT-mTOR activation mediates epiregulin-induced pleiotropic functions in cultured osteoblasts,” Molecular and Cellular Biochemistry, vol. 398, no. 1-2, pp. 105–113, 2015. View at: Publisher Site | Google Scholar
  56. W. V. Berghe, S. Plaisance, E. Boone et al., “p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor.,” Journal of Biological Chemistry, vol. 273, no. 6, pp. 3285–3290, 1998. View at: Publisher Site | Google Scholar
  57. Y. An, H. Zhang, C. Wang et al., “Activation of ROS/MAPK s/NF-κB/NLRP3 and inhibition of efferocytosis in osteoclast-mediated diabetic osteoporosis,” The FASEB Journal, vol. 33, no. 11, pp. 12515–12527, 2019. View at: Publisher Site | Google Scholar
  58. L. Jiating, J. Buyun, and Z. Yinchang, “Role of metformin on osteoblast differentiation in type 2 diabetes,” Biomed Res Int, vol. 2019, Article ID 9203934, 6 pages, 2019. View at: Publisher Site | Google Scholar
  59. D. Thummuri, V. G. M. Naidu, and P. Chaudhari, “Carnosic acid attenuates RANKL-induced oxidative stress and osteoclastogenesis via induction of Nrf2 and suppression of NF-κB and MAPK signalling,” Journal of Molecular Medicine, vol. 95, no. 10, pp. 1065–1076, 2017. View at: Publisher Site | Google Scholar
  60. R. B. Kimble, A. B. Matayoshi, J. L. Vannice, V. T. Kung, C. Williams, and R. Pacifici, “Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period,” Endocrinology, vol. 136, no. 7, pp. 3054–3061, 1995. View at: Publisher Site | Google Scholar
  61. M. N. Weitzmann, S. Cenci, L. Rifas, J. Haug, J. Dipersio, and R. Pacifici, “T cell activation induces human osteoclast formation via receptor activator of nuclear factor κB ligand-dependent and -independent mechanisms,” Journal of Bone and Mineral Research, vol. 16, no. 2, pp. 328–337, 2001. View at: Publisher Site | Google Scholar
  62. L. Mosekilde, H. Beck-Nielsen, O. H. Sørensen et al., “Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study,” Maturitas, vol. 36, no. 3, pp. 181–193, 2000. View at: Publisher Site | Google Scholar
  63. C. Ding, V. Parameswaran, R. Udayan, J. Burgess, and G. Jones, “Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: A longitudinal study.,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 5, pp. 1952–1958, 2008. View at: Publisher Site | Google Scholar
  64. E. R. Gertz, N. E. Silverman, K. S. Wise et al., “Contribution of serum inflammatory markers to changes in bone mineral content and density in postmenopausal women: A 1-year investigation,” Journal of Clinical Densitometry, vol. 13, no. 3, pp. 277–282, 2010. View at: Publisher Site | Google Scholar
  65. K. E. Barbour, L.-Y. Lui, K. E. Ensrud et al., “Inflammatory markers and risk of hip fracture in older white women: The study of osteoporotic fractures,” Journal of Bone and Mineral Research, vol. 29, no. 9, pp. 2057–2064, 2014. View at: Publisher Site | Google Scholar
  66. A. Aydin, Z. Halici, A. Albayrak et al., “Treatment with carnitine enhances bone fracture healing under osteoporotic and/or inflammatory conditions,” Basic & Clinical Pharmacology & Toxicology, vol. 117, no. 3, pp. 173–179, Feb. 2015. View at: Publisher Site | Google Scholar
  67. N. Mody, F. Parhami, T. A. Sarafian, and L. L. Demer, “Oxidative stress modulates osteoblastic differentiation of vascular and bone cells,” Free Radical Biology and Medicine, vol. 31, no. 4, pp. 509–519, 2001. View at: Publisher Site | Google Scholar
  68. B. Watkins, H. E. Lippman, B. L. Le, Y. Li, and M. F. Seifert, “Bioactive fatty acids: Role in bone biology and bone cell function,” Progress in Lipid Research, vol. 40, no. 1-2, pp. 125–148, 2001. View at: Publisher Site | Google Scholar

Copyright © 2020 Yongming Shuai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.